HHS spurs development of smallpox therapeutic to enhance health security

The US Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) will work with BioFactura, Inc., providing expertise and $9.5 million over two years to develop a monoclonal antibody treatment for smallpox. BARDA has options to support additional work, providing up to a total of $67.4 million over five years.

‘The switch’ was supposed to be a major step toward eradicating polio. Now it’s a quandary

Three years ago, health officials phasied out a problematic component of the polio vaccine used in developing countries, and introduced a version that they hoped would put the world on a better footing to eradicate the disease. Now, some health officials are weighing whether “the switch,” as the process was known, needs to be reversed because they fear the new vaccine heightens the risk of the disease spreading indevelopin nations.

A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge

The GEO-LM01 vaccine discussed in this paper provides two sources of viral antigens that mimic a natural viral infection promoting predominantly a balanced T cell response, which is critical for protection against Lassa virus infection.